

CITATION REPORT

List of articles citing

Beta-Blocker Drug Therapy Reduces Secondary Cancer Formation in Breast Cancer and Improves Cancer Specific Survival

DOI: 10.18632/oncotarget.197
Oncotarget, 2010, 1, 628-638.

Source: <https://exaly.com/paper-pdf/87790567/citation-report.pdf>

Version: 2024-04-17

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
362	Targeted therapies: Using β blockers to inhibit breast cancer progression. 2011 , 8, 511-2		70
361	Synthesis and characterization of high-affinity 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene-labeled fluorescent ligands for human β adrenoceptors. 2011 , 54, 6874-87		35
360	Regulation of β adrenergic receptor function: an emphasis on receptor resensitization. 2011 , 10, 3684-91		43
359	Does β adrenoceptor blocker therapy improve cancer survival? Findings from a population-based retrospective cohort study. 2011 , 72, 157-61		91
358	Alpha- and beta-adrenergic receptor (AR) protein expression is associated with poor clinical outcome in breast cancer: an immunohistochemical study. <i>Breast Cancer Research and Treatment</i> , 2011 , 130, 457-63	4.4	70
357	Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohort. <i>Breast Cancer Research and Treatment</i> , 2011 , 129, 549-56	4.4	109
356	Stress influences on anoikis. 2011 , 4, 481-5		24
355	Expanding our therapeutic options: Beta blockers for breast cancer?. 2011 , 29, 2612-6		24
354	Beta blockers and breast cancer mortality: a population- based study. 2011 , 29, 2635-44		383
353	Heterotrimeric G protein signaling in cancer cells with regard to metastasis formation. 2011 , 10, 1086-91		18
352	Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. 2011 , 29, 2645-52		339
351	Expression and functional coupling of liver β - adrenoceptors in the human hepatocellular carcinoma. 2012 , 89, 313-20		22
350	Stimulation of host bone marrow stromal cells by sympathetic nerves promotes breast cancer bone metastasis in mice. 2012 , 10, e1001363		122
349	Will β blockers live up to the maxim of Sir James Black, their creator?. 2012 , 63, 409-11		
348	Personalized Diabetes and Cancer Medicine: A Rationale for Anti-Diabetic Nutrition (Bitter Melon) in a Supportive Setting. 2012 , 8, 66-77		16
347	Anesthesia in patients with cancer disorders. 2012 , 25, 376-84		50
346	Adrenergic Action in Breast Cancer. 2012 , 8, 90-99		2

345	Personalizing cardiovascular disease prevention among breast cancer survivors. 2012 , 27, 515-24	13
344	Norepinephrine promotes the α -integrin-mediated adhesion of MDA-MB-231 cells to vascular endothelium by the induction of a GRO α release. 2012 , 10, 197-207	34
343	The Adrenergic System in Gastrointestinal Cancers. 2012 , 8, 110-115	1
342	Social stress promotes and β -aminobutyric acid inhibits tumor growth in mouse models of non-small cell lung cancer. 2012 , 5, 189-96	53
341	A new approach to reducing postsurgical cancer recurrence: perioperative targeting of catecholamines and prostaglandins. 2012 , 18, 4895-902	71
340	Beta-adrenergic blocking drugs in breast cancer: a perspective review. 2012 , 4, 113-25	41
339	Loss of Hypermethylated in Cancer 1 (HIC1) in breast cancer cells contributes to stress-induced migration and invasion through β adrenergic receptor (ADRB2) misregulation. 2012 , 287, 5379-89	23
338	Nerve Driven Immunity: Noradrenaline and Adrenaline. 2012 , 47-96	6
337	β blockers: a novel class of antitumor agents. 2012 , 5, 391-401	20
336	Pancreatic cancer cells and normal pancreatic duct epithelial cells express an autocrine catecholamine loop that is activated by nicotinic acetylcholine receptors α , β , and γ . 2012 , 10, 239-49	69
335	Stress Related Neuroendocrine Influences in Ovarian Cancer. 2012 , 8, 100-109	1
334	Translational research in oncology: the need of additional in vitro preclinical testing methods for new drugs. 2012 , 18, 3416-20	4
333	Ein Konzept auf dem Prüfstand. 2012 , 17, 34-37	
332	Beta blockers, norepinephrine, and cancer: an epidemiological viewpoint. 2012 , 4, 151-6	36
331	Hiding in plain view: the potential for commonly used drugs to reduce breast cancer mortality. 2012 , 14, 216	32
330	Impact of beta blockers on epithelial ovarian cancer survival. 2012 , 127, 375-8	121
329	Involvement of α - and β -adrenoceptors on breast cancer cell proliferation and tumour growth regulation. 2012 , 166, 721-36	72
328	Circadian rhythms and tumor growth. 2012 , 318, 115-23	65

327	Adrenergic-blocking drugs and melanoma: current state of the art. 2012 , 12, 1461-7		10
326	Intercepting neoplastic progression in lung malignancies via the beta adrenergic (BAR) pathway: implications for anti-cancer drug targets. 2012 , 66, 33-40		19
325	The beta2-adrenergic receptor is a potential prognostic biomarker for human hepatocellular carcinoma after curative resection. 2012 , 19, 3556-65		32
324	Answering the ultimate question "what is the proximal cause of aging?". <i>Aging</i> , 2012 , 4, 861-77	5.6	150
323	The roles of beta-adrenergic receptors in tumorigenesis and the possible use of beta-adrenergic blockers for cancer treatment: possible genetic and cell-signaling mechanisms. <i>Cancer Management and Research</i> , 2012 , 4, 431-45	3.6	18
322	Mind matters in cancer survival. 2012 , 21, 588-93		80
321	Regulation of pancreatic cancer by neuropsychological stress responses: a novel target for intervention. <i>Carcinogenesis</i> , 2012 , 33, 191-6	4.6	67
320	Molecular pathways: beta-adrenergic signaling in cancer. 2012 , 18, 1201-6		394
319	Beta blocker use and colorectal cancer risk: population-based case-control study. 2012 , 118, 3911-9		36
318	Prime Krebsprävention. 2012 , 18, 198-206		
317	Can all beta blockers improve the breast cancer survival?. 2012 , 21, 107-8		8
316	Men's experiences of gynaecomastia and corrective surgery: a qualitative report. 2012 , 21, 108		0
315	The role of Adrenergic receptor signaling in the proliferation of hemangioma-derived endothelial cells. 2013 , 8, 1		77
314	The role of adrenergic signaling in breast cancer biology. 2013 , 13, 161-9		27
313	Antiangiogenic effect of propranolol on the growth of the neuroblastoma xenografts in nude mice. 2013 , 48, 2460-5		8
312	Understanding clinical strategies that may impact tumour growth and metastatic spread at the time of cancer surgery. 2013 , 27, 427-39		24
311	Blockers increase response to chemotherapy via direct antitumour and anti-angiogenic mechanisms in neuroblastoma. <i>British Journal of Cancer</i> , 2013 , 108, 2485-94	8.7	112
310	Therapeutic effect of Blockers in triple-negative breast cancer postmenopausal women. <i>Breast Cancer Research and Treatment</i> , 2013 , 140, 567-75	4.4	85

309	Comorbidities and breast cancer survival: a report from the Shanghai Breast Cancer Survival Study. <i>Breast Cancer Research and Treatment</i> , 2013 , 139, 227-35	4-4	41
308	Exercise therapy as treatment for cardiovascular and oncologic disease after a diagnosis of early-stage cancer. 2013 , 40, 218-28		33
307	Does our "flight and fight" response have a link with cancer?. 2013 , 88, 1185-7		1
306	Effect of β -blockers and other antihypertensive drugs on the risk of melanoma recurrence and death. 2013 , 88, 1196-203		54
305	Lymphovascular and neural regulation of metastasis: shared tumour signalling pathways and novel therapeutic approaches. 2013 , 27, 409-25		10
304	Impact of beta blocker medication in patients with platinum sensitive recurrent ovarian cancer-a combined analysis of 2 prospective multicenter trials by the AGO Study Group, NCIC-CTG and EORTC-GCG. 2013 , 129, 463-6		33
303	Nervous system regulation of the cancer genome. 2013 , 30 Suppl, S10-8		32
302	β -Adrenergic system, a backstage manipulator regulating tumour progression and drug target in cancer therapy. 2013 , 23, 533-42		108
301	Norepinephrine inhibits the migratory activity of pancreatic cancer cells. 2013 , 319, 1744-1758		18
300	Psychosocial factors and hematopoietic stem cell transplantation: potential biobehavioral pathways. 2013 , 38, 2383-93		31
299	Tumor dormancy and the neuroendocrine system: an undisclosed connection?. 2013 , 32, 189-200		18
298	Synthesis of novel isoflavene-propranolol hybrids as anti-tumor agents. 2013 , 21, 1652-60		19
297	Further data on beta-blockers and cancer risk: observational study and meta-analysis of randomized clinical trials. 2013 , 29, 369-78		27
296	Adrenergic modulation of immune cells: an update. 2013 , 45, 55-71		97
295	Beta blockers and angiotensin-converting enzyme inhibitors: purported benefit on breast cancer survival may be explained by aspirin use. <i>Breast Cancer Research and Treatment</i> , 2013 , 139, 507-13	4-4	27
294	Neurotransmitters as regulators of tumor angiogenesis and immunity: the role of catecholamines. 2013 , 8, 7-14		45
293	Biomarker identification in breast cancer: Beta-adrenergic receptor signaling and pathways to therapeutic response. 2013 , 6, e201303003		10
292	Can non-selective beta-blockers prevent hepatocellular carcinoma in patients with cirrhosis?. 2013 , 81, 871-4		17

291	β-blockers: a new role in cancer chemotherapy?. 2013 , 22, 1359-63		18
290	Effects of tobacco constituents and psychological stress on the beta-adrenergic regulation of non-small cell lung cancer and pancreatic cancer: implications for intervention. 2013 , 13, 133-44		13
289	β-blocker usage and colorectal cancer mortality: a nested case-control study in the UK Clinical Practice Research Datalink cohort. 2013 , 24, 3100-6		34
288	Beta-blocker usage and breast cancer survival: a nested case-control study within a UK clinical practice research datalink cohort. 2013 , 42, 1852-61		56
287	Improved survival outcomes with the incidental use of beta-blockers among patients with non-small-cell lung cancer treated with definitive radiation therapy. 2013 , 24, 1312-9		135
286	Use of β-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and risk of breast cancer recurrence: a Danish nationwide prospective cohort study. 2013 , 31, 2265-72		82
285	Gamma-amino butyric acid (GABA) prevents the induction of nicotinic receptor-regulated signaling by chronic ethanol in pancreatic cancer cells and normal duct epithelia. 2013 , 6, 139-48		8
284	Reply: Comment on β-blockers increase response to chemotherapy via direct anti-tumour and anti-angiogenic mechanisms in neuroblastoma β-blockers are potent anti-angiogenic and chemo-sensitising agents, rather than cytotoxic drugs. <i>British Journal of Cancer</i> , 2013 , 109, 2024-5	8.7	4
283	Could β-blockers be a feasible treatment option for lung cancer?. 2013 , 2, 247-249		
282	What is the appropriate approach to treating women with incurable cervical cancer?. 2013 , 11, 348-55		18
281	Expression of β-adrenergic receptors in pediatric malignant brain tumors. 2013 , 5, 221-225		14
280	Targeting of beta adrenergic receptors results in therapeutic efficacy against models of hemangioendothelioma and angiosarcoma. <i>PLoS ONE</i> , 2013 , 8, e60021	3.7	62
279	Differential β-adrenergic receptor expression defines the phenotype of non-tumorigenic and malignant human breast cell lines. <i>Oncotarget</i> , 2014 , 5, 10058-69	3.3	20
278	Anti-tumor activity of the beta-adrenergic receptor antagonist propranolol in neuroblastoma. <i>Oncotarget</i> , 2014 , 5, 161-72	3.3	49
277	Effect of propranolol on IL-10, visfatin, Hsp70, iNOS, TLR2, and survivin in amelioration of tumor progression and survival in Solid Ehrlich Carcinoma-bearing mice. 2014 , 66, 1114-21		15
276	Wirkung von Betablockern beim triple-negativen Mammakarzinom. 2014 , 17, 19-22		
275	Mechanisms of propranolol action in infantile hemangioma. 2014 , 6, e979699		19
274	Koschei the immortal and anti-aging drugs. 2014 , 5, e1552		33

273	Impact of acetylsalicylic Acid on the clinicopathological characteristics and prognosis of patients with invasive breast cancer. 2014 , 9, 261-6		0
272	beta-Adrenoreceptor antagonists reduce cancer cell proliferation, invasion, and migration. 2014 , 52, 1374-81		31
271	Beta-blocker usage after malignant melanoma diagnosis and survival: a population-based nested case-control study. 2014 , 170, 930-8		46
270	Stage-specific associations between beta blocker use and prognosis after colorectal cancer. 2014 , 120, 1178-86		64
269	Perioperative beta-blocker use and survival in lung cancer patients. 2014 , 26, 106-17		35
268	Control of bone remodeling by the peripheral sympathetic nervous system. 2014 , 94, 140-51		91
267	Arterial hypertension and cancer. 2014 , 134, 2269-77		51
266	Perioperative epidural analgesia reduces cancer recurrence after gastro-oesophageal surgery. 2014 , 58, 281-90		44
265	Comparative safety of cardiovascular medication use and breast cancer outcomes among women with early stage breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014 , 144, 405-16	4-4	68
264	Comorbidity burden and guideline-concordant care for breast cancer. 2014 , 62, 482-8		28
263	Adrenergic signaling promotes angiogenesis through endothelial cell-tumor cell crosstalk. 2014 , 21, 783-95		42
262	Earlier and sustained response with incidental use of cardiovascular drugs among patients with low- to medium-grade meningiomas treated with radiosurgery (SRS) or stereotactic radiotherapy (SRT). 2014 , 111, 446-50		3
261	Post-diagnostic use of beta-blockers and the risk of death in patients with prostate cancer. 2014 , 50, 2838-45		26
260	Meta-analysis of the effects of beta blocker on survival time in cancer patients. 2014 , 140, 1179-88		66
259	Evaluation of a novel blood pressure scoring method and its association with clinical response in cancer patients treated with anti-vascular endothelial growth factor therapy. 2014 , 32, 717-22		3
258	Exogenous norepinephrine attenuates the efficacy of sunitinib in a mouse cancer model. 2014 , 33, 21		23
257	Propranolol inhibits glucose metabolism and 18F-FDG uptake of breast cancer through posttranscriptional downregulation of hexokinase-2. 2014 , 55, 439-45		31
256	Association between use of beta-blockers and prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease. 2014 , 65, 635-41		163

255	Reply to "heart failure and breast cancer: emerging controversies regarding some cardioprotective strategies". 2014 , 20, 457	0
254	Monoamine oxidase A suppresses hepatocellular carcinoma metastasis by inhibiting the adrenergic system and its transactivation of EGFR signaling. 2014 , 60, 1225-34	79
253	Quercetin-3-O-glucuronide inhibits noradrenaline binding to α -adrenergic receptor, thus suppressing DNA damage induced by treatment with 4-hydroxyestradiol and noradrenaline in MCF-10A cells. 2014 , 143, 122-9	14
252	Dosage-dependent regulation of cell proliferation and adhesion through dual α -adrenergic receptor/cAMP signals. 2014 , 28, 1342-54	27
251	Beta-blocker usage and prostate cancer survival: a nested case-control study in the UK Clinical Practice Research Datalink cohort. 2014 , 38, 279-85	33
250	A role for cAMP-driven transactivation of EGFR in cancer aggressiveness - therapeutic implications. 2014 , 83, 142-7	10
249	A Her2-let-7- α -AR circuit affects prognosis in patients with Her2-positive breast cancer. 2015 , 15, 832	16
248	Higher vagal activity as related to survival in patients with advanced breast cancer: an analysis of autonomic dysregulation. 2015 , 77, 346-55	57
247	Regulation of nonsmall-cell lung cancer stem cell like cells by neurotransmitters and opioid peptides. 2015 , 137, 2815-24	19
246	Prognostic Value for Incidental Antihypertensive Therapy With β Blockers in Metastatic Colorectal Cancer. 2015 , 94, e719	14
245	Beta Adrenergic Signaling: A Targetable Regulator of Angiosarcoma and Hemangiosarcoma. 2015 , 2, 270-292	5
244	Effect of Chronic Psychological Stress on Liver Metastasis of Colon Cancer in Mice. <i>PLoS ONE</i> , 2015 , 10, e0139978	3-7 21
243	Adrenergic regulation of innate immunity: a review. 2015 , 6, 171	172
242	Chronic stress, sympathetic activation and skeletal metastasis of breast cancer cells. 2015 , 4, 693	6
241	Housing temperature-induced stress drives therapeutic resistance in murine tumour models through α -adrenergic receptor activation. 2015 , 6, 6426	88
240	Non-selective beta-blockers may reduce risk of hepatocellular carcinoma: a meta-analysis of randomized trials. 2015 , 35, 2009-16	43
239	Infantile hemangiomas, retinopathy of prematurity and cancer: a common pathogenetic role of the β -adrenergic system. 2015 , 35, 619-52	29
238	Exploiting the critical perioperative period to improve long-term cancer outcomes. 2015 , 12, 213-26	248

237	[Lymphocyte migration under exposure of homeopathic remedies for periodontal inflammation - a controlled pilot study]. 2015 , 22, 10-7	0
236	β-Adrenergic receptors suppress Rap1B prenylation and promote the metastatic phenotype in breast cancer cells. 2015 , 16, 1364-74	33
235	Pathway-based gene signatures predicting clinical outcome of lung adenocarcinoma. 2015 , 5, 10979	27
234	β-Adrenergic Receptor Signaling in Prostate Cancer. 2014 , 4, 375	46
233	Toward precision medicine in glioblastoma: the promise and the challenges. 2015 , 17, 1051-63	142
232	Comparative analysis of primary tumour and matched metastases in colorectal cancer patients: evaluation of concordance between genomic and transcriptional profiles. 2015 , 51, 791-9	64
231	Long-Term Use of Antihypertensive Agents and Risk of Breast Cancer: A Population-Based Case-Control Study. 2015 , 4, 65-76	21
230	Neural regulation of hematopoiesis, inflammation, and cancer. 2015 , 86, 360-73	148
229	Involvement of sympathetic nerves in bone metastasis. 2015 , 591-597	
228	Delayed-onset of multiple cutaneous infantile hemangiomas due to propranolol: a case report. 2015 , 135, e1064-6	4
227	β-Blockers Reduce Breast Cancer Recurrence and Breast Cancer Death: A Meta-Analysis. 2015 , 15, 426-31	46
226	Drug repurposing in oncology--patient and health systems opportunities. 2015 , 12, 732-42	180
225	Are beta-blockers on the therapeutic horizon for ovarian cancer treatment?. 2015 , 121, 3380-3	7
224	Sympathetic nervous system regulation of the tumour microenvironment. 2015 , 15, 563-72	284
223	The Role of Perioperative Pharmacological Adjuncts in Cancer Outcomes: Beta-Adrenergic Receptor Antagonists, NSAIDs and Anti-fibrinolytics. 2015 , 5, 291-304	2
222	β-Adrenergic blockade mimics the enhancing effect of chronic stress on breast cancer progression. 2015 , 51, 262-70	37
221	Propranolol induces a favourable shift of anti-tumor immunity in a murine spontaneous model of melanoma. <i>Oncotarget</i> , 2016 , 7, 77825-77837	3-3 44
220	Anaesthesia in Cancer Surgery: Can it Affect Cancer Survival?. 2016 , 11, 4-20	9

219	Re-Use of Established Drugs for Anti-Metastatic Indications. 2016 , 5,	7
218	Use of beta-blockers, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and breast cancer survival: Systematic review and meta-analysis. 2016 , 139, 212-9	49
217	βBlocker use and mortality in cancer patients: systematic review and meta-analysis of observational studies. 2016 , 25, 440-8	30
216	Resting heart rate is an independent predictor of death in patients with colorectal, pancreatic, and non-small cell lung cancer: results of a prospective cardiovascular long-term study. 2016 , 18, 1524-1534	42
215	Long-term Consequences of the Acute Neural-Inflammatory Stress Response in the Cancer Surgical Patient: New Findings and Perspectives. 2016 , 54, 58-71	4
214	Beta blockers and cancer prognosis - The role of immortal time bias: A systematic review and meta-analysis. 2016 , 47, 1-11	61
213	Immunological and pleiotropic effects of individual βblockers and their relevance in cancer therapies. 2016 , 25, 501-5	10
212	Propranolol sensitizes thyroid cancer cells to cytotoxic effect of vemurafenib. 2016 , 36, 1576-84	15
211	Synthesis of Enantiopure Drugs and Drug Intermediates Using In Silico Generated Archetype Biocatalyst: A Case Study Using Alprenolol as a Model Drug. 2016 , 1, 871-876	5
210	Cancer cells become less deformable and more invasive with activation of βadrenergic signaling. 2016 , 129, 4563-4575	45
209	Repurposing of approved cardiovascular drugs. 2016 , 14, 269	49
208	Sympathectomy reduces tumor weight and affects expression of tumor-related genes in melanoma tissue in the mouse. 2016 , 19, 528-34	20
207	Chronic stress in mice remodels lymph vasculature to promote tumour cell dissemination. 2016 , 7, 10634	169
206	Breast cancer and social environment: getting by with a little help from our friends. 2016 , 18, 54	42
205	Non-selective βblockers in advanced cirrhosis: a critical review of the effects on overall survival and renal function. 2016 , 3, e000104	8
204	Inhibition of α ₂ -adrenergic receptor reduces triple-negative breast cancer brain metastases: The potential benefit of perioperative βblockade. 2016 , 35, 3135-42	55
203	Role of sympathetic nerves in the establishment of metastatic breast cancer cells in bone. 2016 , 5, 132-134	10
202	Effective Management of Advanced Angiosarcoma by the Synergistic Combination of Propranolol and Vinblastine-based Metronomic Chemotherapy: A Bench to Bedside Study. 2016 , 6, 87-95	75

201	Selective β -AR Blockage Suppresses Colorectal Cancer Growth Through Regulation of EGFR-Akt/ERK1/2 Signaling, G1-Phase Arrest, and Apoptosis. <i>Journal of Cellular Physiology</i> , 2016 , 231, 459-72	7	39
200	Obstructive sleep apnea and cancer: Epidemiologic links and theoretical biological constructs. 2016 , 27, 43-55		71
199	The potential anticancer effect of beta-blockers and the genetic variations involved in the interindividual difference. 2016 , 17, 74-9		8
198	Propranolol Attenuates Surgical Stress-Induced Elevation of the Regulatory T Cell Response in Patients Undergoing Radical Mastectomy. 2016 , 196, 3460-9		52
197	The β -adrenoceptor activates a positive cAMP-calcium feedforward loop to drive breast cancer cell invasion. 2016 , 30, 1144-54		35
196	Adrenergic Stimulation of DUSP1 Impairs Chemotherapy Response in Ovarian Cancer. 2016 , 22, 1713-24		47
195	A Novel Effect of β Adrenergic Receptor on Mammary Branching Morphogenesis and its Possible Implications in Breast Cancer. 2017 , 22, 43-57		11
194	Glucose Metabolism in Cancer and Ischemia: Possible Therapeutic Consequences of the Warburg Effect. 2017 , 69, 177-183		10
193	Neurons generated from carcinoma stem cells support cancer progression. 2017 , 2, 16036		43
192	Label-Free Dynamic Mass Redistribution Reveals Low-Density, Prosurvival β -Adrenergic Receptors in Human SW480 Colon Carcinoma Cells. 2017 , 361, 219-228		3
191	Epidemiology of Cardio-Oncology. 2017 , 1-14		1
190	Perioperative COX-2 and β Adrenergic Blockade Improves Metastatic Biomarkers in Breast Cancer Patients in a Phase-II Randomized Trial. 2017 , 23, 4651-4661		131
189	Heart rate and its reduction in chronic heart failure and beyond. 2017 , 19, 1230-1241		24
188	Metastatic triple-negative breast cancer patient with tumor mutation experienced 11 months progression-free survival on bortezomib monotherapy without adverse events after ending standard treatments with grade 3 adverse events. 2017 , 3,		9
187	Beta blockers and improved progression-free survival in patients with advanced HER2 negative breast cancer: a retrospective analysis of the ROSE/TRIO-012 study. 2017 , 28, 1836-1841		35
186	Estrogen- and stress-induced DNA damage in breast cancer and chemoprevention with dietary flavonoid. 2017 , 39, 10		28
185	Immunological consequences of immunization with tumor lysate vaccine and propranolol as an adjuvant: A study on cytokine profiles in breast tumor microenvironment. 2017 , 181, 63-70		8
184	Epinephrine Stimulates Cell Proliferation and Induces Chemoresistance in Myeloma Cells through the β Adrenoreceptor in vitro. 2017 , 138, 103-110		8

183	Drug repurposing in cancer. 2017 , 124, 74-91		146
182	Racial differences in the effects of comorbidity on breast cancer-specific survival. 2017 , 28, 809-817		6
181	Use of Antihypertensive Medications and Risk of Adverse Breast Cancer Outcomes in a SEER-Medicare Population. 2017 , 26, 1603-1610		17
180	Topically Applied Carvedilol Attenuates Solar Ultraviolet Radiation Induced Skin Carcinogenesis. 2017 , 10, 598-606		14
179	Sympathetic Signaling Reactivates Quiescent Disseminated Prostate Cancer Cells in the Bone Marrow. 2017 , 15, 1644-1655		42
178	Commonly used medications and endometrial cancer survival: a population-based cohort study. <i>British Journal of Cancer</i> , 2017 , 117, 432-438	8.7	24
177	Repurposing propranolol as a drug for the treatment of retinal haemangioblastomas in von Hippel-Lindau disease. 2017 , 12, 122		17
176	Effects of Z-venusol, isolated from <i>Gunnera perpensa</i> L., on IL-6 and cAMP activity in human breast cancer cells in vitro. 2017 , 108, 96-99		1
175	Perioperative Anesthesia Care and Tumor Progression. 2017 , 124, 1697-1708		92
174	Beta-blockers improve survival outcomes in patients with multiple myeloma: a retrospective evaluation. 2017 , 92, 50-55		30
173	Tumor Immune Microenvironment in Cancer Progression and Cancer Therapy. 2017 ,		6
172	The Impact of Housing Temperature-Induced Chronic Stress on Preclinical Mouse Tumor Models and Therapeutic Responses: An Important Role for the Nervous System. 2017 , 1036, 173-189		15
171	Protective Role of the Hepatic Vagus Nerve against Liver Metastasis in Mice. 2017 , 24, 341-347		3
170	Accelerated tumor growth under intermittent hypoxia is associated with hypoxia-inducible factor-1-dependent adaptive responses to hypoxia. <i>Oncotarget</i> , 2017 , 8, 61592-61603	3.3	19
169	From rapalogs to anti-aging formula. <i>Oncotarget</i> , 2017 , 8, 35492-35507	3.3	61
168	Drug Repurposing Review. 2017 , 11-47		4
167	Metformin and propranolol combination prevents cancer progression and metastasis in different breast cancer models. <i>Oncotarget</i> , 2017 , 8, 2874-2889	3.3	36
166	Phosphoproteome profiling provides insight into the mechanism of action for carvedilol-mediated cancer prevention. 2018 , 57, 997-1007		8

165	Cardiovascular Disease and Breast Cancer: Where These Entities Intersect: A Scientific Statement From the American Heart Association. 2018 , 137, e30-e66		300
164	Beta blocker use correlates with better overall survival in metastatic melanoma patients and improves the efficacy of immunotherapies in mice. 2018 , 7, e1405205		73
163	Beta2-adrenergic signaling affects the phenotype of human cardiac progenitor cells through EMT modulation. 2018 , 127, 41-48		16
162	Motivation for Launching a Cancer Metastasis Inhibition (CMI) Program. 2018 , 13, 61-68		5
161	Dexmedetomidine promotes metastasis in rodent models of breast, lung, and colon cancers. 2018 , 120, 188-196		47
160	Concurrent new drug prescriptions and prognosis of early breast cancer: studies using the Danish Breast Cancer Group clinical database. 2018 , 57, 120-128		8
159	Effect of antihypertensive drugs on breast cancer risk in female hypertensive patients: Evidence from observational studies. 2018 , 40, 22-27		14
158	Analysis of Tumor Biology to Advance Cancer Health Disparity Research. 2018 , 188, 304-316		17
157	Triple negative breast cancer: Emerging therapeutic modalities and novel combination therapies. 2018 , 62, 110-122		198
156	Propranolol enhanced the anti-tumor effect of sunitinib by inhibiting proliferation and inducing G0/G1/S phase arrest in malignant melanoma. <i>Oncotarget</i> , 2018 , 9, 802-811	3.3	12
155	Disease or not, aging is easily treatable. <i>Aging</i> , 2018 , 10, 3067-3078	5.6	29
154	βblockers inhibit the viability of breast cancer cells by regulating the ERK/COX-2 signaling pathway and the drug response is affected by ADRB2 single-nucleotide polymorphisms. 2019 , 41, 341-350		10
153	Perioperative Stress, Inflammation, and Cancer Progression: Opportunities for Intervention in Breast and Colorectal Cancer Surgery Utilizing Beta-Adrenergic Blockade and COX-2 Inhibition. 2018 , 8, 386-392		2
152	Propranolol Promotes Glucose Dependence and Synergizes with Dichloroacetate for Anti-Cancer Activity in HNSCC. <i>Cancers</i> , 2018 , 10,	6.6	14
151	Propranolol for the treatment of vascular sarcomas. 2018 , 10, 51-58		14
150	βARs stimulation in osteoblasts promotes breast cancer cell adhesion to bone marrow endothelial cells in an IL-1β and selectin-dependent manner. 2018 , 13, 1-10		18
149	βAdrenergic receptor modulates mitochondrial metabolism and disease progression in recurrent/metastatic HPV(+) HNSCC. 2018 , 7, 81		11
148	Association between perioperative beta blocker use and cancer survival following surgical resection. 2018 , 44, 1164-1169		19

147	Opticalin vivoandex vivoimaging of glioma cells migration via the cerebral vessels: Prospective clinical application of the beta2-adrenoreceptors blockade for glioma treatment. 2018 , 11, 1850025	3
146	Impact of the Autonomic Nervous System on the Skeleton. 2018 , 98, 1083-1112	64
145	Adrenergic Signaling: A Targetable Checkpoint Limiting Development of the Antitumor Immune Response. 2018 , 9, 164	59
144	Repurposing existing medications as cancer therapy: design and feasibility of a randomized pilot investigating propranolol administration in patients receiving hematopoietic cell transplantation. 2018 , 18, 593	15
143	Anti-tumor effects of propranolol: Adjuvant activity on a transplanted murine breast cancer model. 2018 , 104, 45-51	10
142	Role of the nervous system in cancer metastasis. 2018 , 37, 5	63
141	Effect of beta-blockers on cancer recurrence and survival: a meta-analysis of epidemiological and perioperative studies. 2018 , 121, 45-57	59
140	Resting heart rate is an independent predictor of advanced colorectal adenoma recurrence. <i>PLoS ONE</i> , 2018 , 13, e0193753	3-7 14
139	Genetic manipulation of autonomic nerve fiber innervation and activity and its effect on breast cancer progression. 2019 , 22, 1289-1305	93
138	Beyond the boundaries of cardiology: Still untapped anticancer properties of the cardiovascular system-related drugs. 2019 , 147, 104326	7
137	The Epithelial-Myeloid-Transition (EMyET) of cancer cells as a wrongly perceived primary inflammatory process eventually progressing to a bone remodeling malignancy: the alternative pathway for Epithelial- Mesenchymal-Transition hypothesis (EMT)?. 2019 , 10, 3798-3809	4
136	The beta adrenergic receptor antagonist propranolol alters mitogenic and apoptotic signaling in late stage breast cancer. 2019 , 42, 155-165	25
135	Inhibitory role of G-coupled receptors on cAMP-driven cancers with focus on opioid receptors in lung adenocarcinoma and its stem cells. 2019 , 111, 299-311	1
134	Belinostat suppresses cell proliferation by inactivating Wnt/ β catenin pathway and promotes apoptosis through regulating PKC pathway in breast cancer. 2019 , 47, 3955-3960	11
133	The perioperative period: a critical yet neglected time window for reducing the recurrence risk of endometriosis?. 2019 , 34, 1858-1865	9
132	Manipulation of Ambient Housing Temperature To Study the Impact of Chronic Stress on Immunity and Cancer in Mice. 2019 , 202, 631-636	23
131	Differential Free Intracellular Calcium Release by Class II Antiarrhythmics in Cancer Cell Lines. 2019 , 369, 152-162	5
130	Prognostic significance of β and α -adrenoceptor gene expression in breast cancer patients. 2019 , 85, 2143-2154	14

129	Evaluation of the safety and effectiveness of oral propranolol in patients with von Hippel-Lindau disease and retinal hemangioblastomas: phase III clinical trial. 2019 , 4, e000203	7
128	Beta blockade as adjunctive breast cancer therapy: A review. 2019 , 138, 173-177	14
127	Perioperative Administration of an Intravenous Beta-Blocker Landiolol Hydrochloride in Patients with Lung Cancer: A Japanese Retrospective Exploratory Clinical Study. 2019 , 9, 5217	7
126	Cardiovascular medication use and risks of colon cancer recurrences and additional cancer events: a cohort study. 2019 , 19, 270	5
125	Fear stress enhanced xenograft pancreatic tumor growth through activating epithelial-mesenchymal transition. 2019 , 19, 377-382	2
124	Treatment of chemotherapy-associated cardiomyopathy. 2019 , 34, 296-302	2
123	Landiolol, an ultra-short acting beta-1 blocker, for preventing postoperative lung cancer recurrence: study protocol for a phase III, multicenter randomized trial with two parallel groups of patients. 2019 , 20, 715	4
122	Can propranolol prevent progression of melanoma?. 2019 , 32, 1-5	3
121	Circulating epinephrine is not required for chronic stress to enhance metastasis. 2019 , 99, 191-195	19
120	Baseline and Postoperative C-reactive Protein Levels Predict Long-Term Survival After Lung Metastasectomy. 2019 , 26, 869-875	9
119	Using human experience to identify drug repurposing opportunities: theory and practice. 2019 , 85, 680-689	4
118	Epigenetics in Health and Disease. 2019 , 647-731	
117	Cancer cachexia: getting to the heart of the matter. 2019 , 40, e17-e19	3
116	E-Cigarettes and Cancer Risk. 2020 , 13, 137-144	17
115	Can stress promote the pathophysiology of brain metastases? A critical review of biobehavioral mechanisms. 2020 , 87, 860-880	1
114	βAdrenergic Signaling in Lung Cancer: A Potential Role for Beta-Blockers. 2020 , 15, 27-36	15
113	Preoperative βBlockade with Propranolol Reduces Biomarkers of Metastasis in Breast Cancer: A Phase II Randomized Trial. 2020 , 26, 1803-1811	52
112	Unintended Effects of GPCR-Targeted Drugs on the Cancer Phenotype. 2020 , 41, 1006-1022	5

111	Beta-adrenergic blocker inhibits oral carcinogenesis and reduces tumor invasion. 2020 , 86, 681-686	2
110	Stress and cancer. Part II: Therapeutic implications for oncology. 2020 , 346, 577312	10
109	Does sympathetic nervous system modulate tumor progression? A narrative review of the literature. 2020 , 9, 106-116	2
108	Impairment of Hypoxia-Induced CA IX by Beta-Blocker Propranolol-Impact on Progression and Metastatic Potential of Colorectal Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3 1
107	Nonselective β -adrenergic blockade impacts pancreatic cancer tumor biology, decreases perineural invasion and improves patient survival. 2020 , 3, 8-8	
106	Beta adrenergic receptor activation inhibits oral cancer migration and invasiveness. 2020 , 118, 104865	8
105	Synergy Between Embedding and Protein Functional Association Networks for Drug Label Prediction using Harmonic Function. 2020 , PP,	1
104	β Adrenoceptor Activation in Breast MCF-10A Cells Induces a Pattern of Catecholamine Production Similar to that of Tumorigenic MCF-7 Cells. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3 3
103	Stress reduction strategies in breast cancer: review of pharmacologic and non-pharmacologic based strategies. 2020 , 42, 719-734	15
102	Angiotensin Receptor Blockers Associated with Improved Breast Cancer Survival-A Nationwide Cohort Study from Finland. 2020 , 29, 2376-2382	9
101	Drug Repurposing for Triple-Negative Breast Cancer. 2020 , 10,	14
100	Beta-Blockers and Cancer: Where Are We?. 2020 , 13,	12
99	Assessing the effects of beta-blockers on pancreatic cancer risk: A nested case-control study. 2020 , 29, 599-604	4
98	Prognostic and Predictive Impact of Beta-2 Adrenergic Receptor Expression in HER2-Positive Breast Cancer. 2020 , 20, 262-273.e7	5
97	α -Adrenergic Signalling Promotes Cell Migration by Upregulating Expression of the Metastasis-Associated Molecule LYPD3. 2020 , 9,	7
96	Increased cancer incidence in "cold" countries: An (un)sympathetic connection?. 2020 , 89, 102538	5
95	Impact of concomitant medication use and immune-related adverse events on response to immune checkpoint inhibitors. 2020 , 12, 141-149	8
94	Nerves in cancer. 2020 , 20, 143-157	96

93	Sympathetic improvement of cancer vaccine efficacy. 2020 , 16, 1888-1890		2
92	Targeting Glucose Transporters for Breast Cancer Therapy: The Effect of Natural and Synthetic Compounds. <i>Cancers</i> , 2020 , 12,	6.6	39
91	Comedications influence immune infiltration and pathological response to neoadjuvant chemotherapy in breast cancer. 2020 , 9, 1677427		5
90	Agonist Effects of Propranolol on Non-Tumor Human Breast Cells. 2020 , 9,		3
89	Propranolol inhibits molecular risk markers in HCT recipients: a phase 2 randomized controlled biomarker trial. 2020 , 4, 467-476		20
88	The Impact of Beta Blockers on Survival Outcomes in Patients With Non-small-cell Lung Cancer Treated With Immune Checkpoint Inhibitors. 2021 , 22, e57-e62		14
87	Phase I Clinical Trial of Combination Propranolol and Pembrolizumab in Locally Advanced and Metastatic Melanoma: Safety, Tolerability, and Preliminary Evidence of Antitumor Activity. 2021 , 27, 87-95		27
86	Anesthesia and Cancer Recurrence. 2021 , 13-41		
85	Adrenergic Signaling in Immunotherapy of Cancer: Friend or Foe?. <i>Cancers</i> , 2021 , 13,	6.6	6
84	Sympathetic activity in breast cancer and metastasis: partners in crime. 2021 , 9, 9		11
83	The Potent Cytotoxic and Oxidative Effects of β Selective ICI-118,551 on Breast Adenocarcinoma Cell Lines with Different Aggressiveness.		
82	Control of immune cell trafficking through inter-organ communication. 2021 , 33, 327-335		2
81	Norepinephrine Enhances Aerobic Glycolysis and May Act as a Predictive Factor for Immunotherapy in Gastric Cancer. 2021 , 2021, 5580672		2
80	Propranolol suppresses gastric cancer cell growth by regulating proliferation and apoptosis. 2021 , 24, 1037-1049		2
79	Beta-blockers in early-stage breast cancer: a systematic review and meta-analysis. 2021 , 6, 100066		2
78	Anti-Angiogenic Therapy: Current Challenges and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	23
77	Role of the nervous system in cancers: a review. <i>Cell Death Discovery</i> , 2021 , 7, 76	6.9	12
76	Association Between Antihypertensive Medication Use and Breast Cancer: A Systematic Review and Meta-Analysis. 2021 , 12, 609901		3

75	Neurobiology of Cancer: Introduction of New Drugs in the Treatment and Prevention of Cancer. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	1
74	Chronic propranolol treatment moderately attenuated development of N-methyl-N-nitrosourea-induced mammary carcinoma in female rats. 2021 , 32, 1011-1018		1
73	Mechanisms Supporting the Use of Beta-Blockers for the Management of Breast Cancer Bone Metastasis. <i>Cancers</i> , 2021 , 13,	6.6	3
72	The cytotoxic and apoptotic effects of beta-blockers with different selectivity on cancerous and healthy lung cell lines. 2021 , 48, 4009-4019		1
71	Breast Cancer and Anaesthesia: Genetic Influence. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	0
70	Subclinical cardiac damage in cancer patients before chemotherapy. 2021 , 1		0
69	B-blockers in advanced cirrhosis: More friend than enemy. 2021 , 27, 425-436		3
68	Role of β and β adrenergic signaling in phenotypic targeting: significance in benign and malignant urologic disease. 2021 , 19, 78		2
67	Antihypertensive medications and risks of recurrence and mortality in luminal, triple-negative, and HER2-overexpressing breast cancer. 2021 , 32, 1375-1384		0
66	Propranolol Inhibits the Proliferation of Human Glioblastoma Cell Lines through Notch1 and Hes1 Signaling System. 2021 , 64, 716-725		2
65	Involvement of sympathetic nerves in bone metastasis. 2022 , 863-869		
64	Dynamic Effects of CAM Techniques on Inflammation and Emotional States: An Integrative Single-Case Study on a Breast Cancer Survivor. <i>Integrative Cancer Therapies</i> , 2021 , 20, 1534735420977697		2
63	Perioperative Biologic Perturbation and Cancer Surgery: Targeting the Adrenergic-Inflammatory Response and Microcirculatory Dysregulation. 2017 , 83-107		2
62	B-blocker use is not associated with improved clinical outcomes in women with breast cancer: a meta-analysis. <i>Bioscience Reports</i> , 2020 , 40,	4.1	5
61	An overview of cancer health disparities: new approaches and insights and why they matter. <i>Carcinogenesis</i> , 2021 , 42, 2-13	4.6	11
60	Operative Trauma and Blood Loss - Impact on Tumor Growth and Recurrence. <i>Shock</i> , 2021 , 55, 455-464	3.4	3
59	Adrenergic signaling modulates cancer cell mechanotype through a RhoA-ROCK-myosin II axis.		2
58	Anti-hypertensive Calcium-Blocking Drugs Induce a Change in Viscoelasticity of MCF-7 Cancer Cells. 2020 ,		2

57	A network-based classification model for deriving novel drug-disease associations and assessing their molecular actions. <i>PLoS ONE</i> , 2014 , 9, e111668	3.7	28
56	Adrenergic Receptor Signaling Regulates the Response of Tumors to Ionizing Radiation. <i>Radiation Research</i> , 2019 , 191, 585-589	3.1	17
55	Recent progress in targeting cancer. <i>Aging</i> , 2011 , 3, 1154-62	5.6	9
54	Non-selective beta blockers inhibit angiosarcoma cell viability and increase progression free- and overall-survival in patients diagnosed with metastatic angiosarcoma. <i>Oncoscience</i> , 2018 , 5, 109-119	0.8	24
53	NO-dependent attenuation of TPA-induced immunoinflammatory skin changes in Balb/c mice by pindolol, heptaminol or ATRA, but not by verapamil. <i>Oncotarget</i> , 2016 , 7, 47576-47585	3.3	2
52	Propranolol induced G0/G1/S phase arrest and apoptosis in melanoma cells via AKT/MAPK pathway. <i>Oncotarget</i> , 2016 , 7, 68314-68327	3.3	44
51	Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth. <i>Oncotarget</i> , 2014 , 5, 5453-71	3.3	112
50	Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment. <i>Oncotarget</i> , 2011 , 2, 797-809	3.3	154
49	NCIQ provocative questions on cancer: some answers to ignite discussion. <i>Oncotarget</i> , 2011 , 2, 1352-67	3.3	46
48	Increased expression of SUMO1P3 predicts poor prognosis and promotes tumor growth and metastasis in bladder cancer. <i>Oncotarget</i> , 2016 , 7, 16038-48	3.3	36
47	Common drugs and treatments for cancer and age-related diseases: revitalizing answers to NCIQ provocative questions. <i>Oncotarget</i> , 2012 , 3, 1711-24	3.3	35
46	Prevention of pancreatic cancer in a hamster model by cAMP decrease. <i>Oncotarget</i> , 2016 , 7, 44430-44443	3.3	6
45	Targeting Different Pathways Using Novel Combination Therapy in Triple Negative Breast Cancer. <i>Current Cancer Drug Targets</i> , 2020 , 20, 586-602	2.8	39
44	Neural Regulation of Pancreatic Cancer: A Novel Target for Intervention. <i>Cancers</i> , 2015 , 7, 1292-312	6.6	12
43	Carvedilol may attenuate liver cirrhosis by inhibiting angiogenesis through the VEGF-Src-ERK signaling pathway. <i>World Journal of Gastroenterology</i> , 2015 , 21, 9566-76	5.6	24
42	Associations between metabolic syndrome and gynecologic cancer. <i>Obstetrics and Gynecology Science</i> , 2020 , 63, 215-224	1.9	10
41	Does beta-blocker therapy improve the survival of patients with metastatic non-small cell lung cancer?. <i>Asian Pacific Journal of Cancer Prevention</i> , 2013 , 14, 6109-14	1.7	30
40	Are beta blockers new potential anticancer agents?. <i>Asian Pacific Journal of Cancer Prevention</i> , 2014 , 15, 9567-74	1.7	13

39	Adrenergic Receptors : New Target in Breast Cancer. <i>Asian Pacific Journal of Cancer Prevention</i> , 2015 , 16, 8031-9	1.7	3
38	Calcium-channel-blockers exhibit divergent regulation of cancer extravasation through the mechanical properties of cancer cells and underlying vascular endothelial cells. <i>Cell Biochemistry and Biophysics</i> , 2021 , 1	3.2	0
37	Anaesthesia and Cancer Recurrence. <i>Journal of Anesthesia & Critical Care: Open Access</i> , 2014 , 1,	1	
36	Das Karzinom in der Polarität zwischen Stoffwechsel- und Nerven-Sinnes-System [Konsequenzen für die Therapie. <i>Der Merkurstab</i> , 2017 , 70, 221-228	0.2	
35	Immunological consequences of ageing microvascular hemodynamic changes in view of cancer development and treatment. <i>Oncotarget</i> , 2017 , 8, 69047-69061	3.3	
34	Hypertension related to the antitumor treatment with angiogenesis inhibitors: an iatrogenic hypertension. <i>Arterial Hypertension (Russian Federation)</i> , 2018 , 24, 384-395	0.7	1
33	Postoperative atrial fibrillation does not impact on overall survival after esophagectomy in patients with thoracic esophageal cancer: results from a randomized, double-blind, placebo-controlled trial. <i>Oncotarget</i> , 2020 , 11, 2414-2423	3.3	1
32	Drug Repurposing in Oncotherapeutics.		1
31	Role of adrenergic receptor signalling in neuroimmune communication.. <i>Current Research in Immunology</i> , 2021 , 2, 202-217	1	1
30	Social Genomics and Cancer: Neural Regulation of the Cancer Genome. 2022 , 345-357		
29	A metastasis-on-a-chip approach to explore the sympathetic modulation of breast cancer bone metastasis.. <i>Materials Today Bio</i> , 2022 , 13, 100219	9.9	0
28	Post-diagnostic beta blocker use and breast cancer-specific mortality: a population-based cohort study.. <i>Breast Cancer Research and Treatment</i> , 2022 , 193, 225	4.4	0
27	Targeting tumor innervation: premises, promises, and challenges.. <i>Cell Death Discovery</i> , 2022 , 8, 131	6.9	1
26	Contribution of adrenergic mechanisms for the stress-induced breast cancer carcinogenesis.. <i>Journal of Cellular Physiology</i> , 2022 ,	7	0
25	Association of Hypertension and Breast Cancer: Antihypertensive Drugs as an Effective Adjunctive in Breast Cancer Therapy.. <i>Cancer Management and Research</i> , 2022 , 14, 1323-1329	3.6	
24	Stress in Metastatic Breast Cancer: To the Bone and Beyond.. <i>Cancers</i> , 2022 , 14,	6.6	0
23	Sensory nerves enhance triple-negative breast cancer migration and metastasis via the axon guidance molecule PlexinB3.		1
22	Tissue and Drug Specificity of Drug Sensitivities in Different Cancer Cell Lines. 2021 ,		

21	Biobehavioral Pathways and Cancer Progression: Insights for Improving Well-Being and Cancer Outcomes.. <i>Integrative Cancer Therapies</i> , 2022 , 21, 15347354221096081	3	2
20	Impact of β blockers on survival outcomes in patients with unresectable hepatocellular carcinoma. <i>Hepatic Oncology</i> , 2022 , 9,	4	
19	β blockers and breast cancer survival by molecular subtypes: a population-based cohort study and meta-analysis. <i>British Journal of Cancer</i> ,	8.7	0
18	Adrenergic receptors in breast cancer. <i>Progress in Molecular Biology and Translational Science</i> , 2022 ,	4	
17	Beta 2-Adrenergic Receptor in Circulating Cancer-Associated Cells Predicts for Increases in Stromal Macrophages in Circulation and Patient Survival in Metastatic Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2022 , 23, 7299	6.3	
16	Dissecting the role of cell signaling versus CD8+ T cell modulation in propranolol antitumor activity. 2022 , 100, 1299-1306		0
15	Effect of chronic stress on tumorigenesis and development. 2022 , 79,		
14	Interactive exploration of a global clinical network from a large breast cancer cohort. 2022 , 5,		
13	Therapeutics targeting the metastatic breast cancer bone microenvironment. 2022 , 239, 108280		2
12	The Sympathetic Nervous System Contributes to the Establishment of Pre-Metastatic Pulmonary Microenvironments. 2022 , 23, 10652		0
11	Sensory nerves enhance triple-negative breast cancer invasion and metastasis via the axon guidance molecule PlexinB3. 2022 , 8,		1
10	Profiling the Adrenergic System in Breast Cancer and the Development of Metastasis. 2022 , 14, 5518		2
9	Cancer Metastasis and Treatment Resistance: Mechanistic Insights and Therapeutic Targeting of Cancer Stem Cells and the Tumor Microenvironment. 2022 , 10, 2988		0
8	Breast cancer and neurotransmitters: emerging insights on mechanisms and therapeutic directions.		0
7	Blockade of β Adrenergic Receptors by Nebivolol Enables Tumor Control Potential for Uveal Melanoma in 3D Tumor Spheroids and 2D Cultures. 2023 , 24, 5894		0
6	Potential cardioprotective and anticancer effects of carvedilol either free or as loaded nanoparticles with or without doxorubicin in solid Ehrlich carcinoma-bearing mice. 2023 , 465, 116448		0
5	Chronic stress in solid tumor development: from mechanisms to interventions. 2023 , 30,		0
4	The Renin-Angiotensin System and Cancer. 2023 , 277-339		0

- 3 Dopamine-Loaded Polymer-Drug Conjugates for Potential Synergistic Anti-Cancer Treatment. **2022**, 61, 1003-1020 ○
- 2 The Secretome of Parental and Bone Metastatic Breast Cancer Elicits Distinct Effects in Human Osteoclast Activity after Activation of α Adrenergic Signaling. **2023**, 13, 622 ○
- 1 Diagnostic role of heart rate variability in breast cancer and its relationship with peripheral serum carcinoembryonic antigen. **2023**, 18, e0282221 ○